Zhenning Wang

Jiangsu University — China

Medicine · Health Sciences

65h-index14.7kcitations629works4.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Gastric Cancer Management and Outcomes(131), Cancer-related molecular mechanisms research(60), Metastasis and carcinoma case studies(60), Colorectal Cancer Surgical Treatments(48), RNA modifications and cancer(45)

Publications620 total

Self-assembling nanoscale platforms for curcumin delivery using cerebroprotein hydrolysate/crown ether/quaternary ammonium salts/phospholipid: pH-responsive release, in vivo targeting real-time monitoring and visualization analysis
European Polymer Journal·2025
LLDT-8 attenuates brain metastasis in non-small cell lung cancer <i>via</i> selective p53 activation
RSC Medicinal Chemistry·2025Open Access
Supplementary Figure 5 from A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors
2025Open Access
Supplementary Table 2 from A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors
2025Open Access
Supplementary Table 6 from A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors
2025Open Access
Supplementary Table 5 from A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors
2025Open Access
Supplementary Table 4 from A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors
2025Open Access
Data from A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors
2025Open Access
Supplementary Table 3 from A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors
2025Open Access
Supplementary Table 8 from A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors
2025Open Access
Supplementary Figure 6 from A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors
2025Open Access
Supplementary Figure 7 from A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors
2025Open Access
Supplementary Table 7 from A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors
2025Open Access
Supplementary Figure 3 from A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors
2025Open Access
Supplementary Figure 4 from A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors
2025Open Access
Supplementary Figure 2 from A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors
2025Open Access
Supplementary Table 1 from A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors
2025Open Access
A Wearable System Featuring Biomimetic Spatially Distributed Iontronic Sensing Array for Dynamic Monitoring of Deep Tissue Modulus
Advanced Science·2025Open Access
Photophysical behavior of sulfur-oxidized sulfone and trifluoromethyl-BODIPY: Insight into the relationship between crystal structure and tumor cell imaging
Spectrochimica Acta Part A Molecular and Biomolecular Spectroscopy·2025
The Radio Flare and Multiwavelength Afterglow of the Short GRB 231117A: Energy Injection from a Violent Shell Collision
The Astrophysical Journal·2025Open Access
page 1 of 31Next →

Frequent Co-authors

Yongxi Song(28), Peng Gao(18), Huimian Xu(16), Jingxu Sun(14), Yingying Xu(11), Xiaowan Chen(11), Xuanzhang Huang(11), Junhua Zhao(9), Chengzhong Xing(7), Yuchong Yang(7), Zhi‐Feng Miao(7), Jaffer A. Ajani(6), Shumei Song(6), Yan Xu(6), Bin Ma(5), Zhenyu Yue(4), Zhe Sun(4), Jason C. Mills(4), Kazuto Harada(4), Melissa Pool Pizzi(4)